NasdaqCM - Delayed Quote • USD
Viking Therapeutics, Inc. (VKTX)
At close: April 25 at 4:00 PM EDT
Pre-Market: 9:09 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 10 |
| Avg. Estimate | -0.26 | -0.28 | -1.1 | -1.54 |
| Low Estimate | -0.32 | -0.32 | -1.27 | -2.11 |
| High Estimate | -0.17 | -0.2 | -0.85 | -0.96 |
| Year Ago EPS | -0.19 | -0.23 | -0.91 | -1.1 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 10 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.19 | -0.22 | -0.25 | -0.28 |
| EPS Actual | -0.19 | -0.23 | -0.25 | -0.26 |
| Difference | 0 | -0.01 | 0 | 0.02 |
| Surprise % | 0.00% | -4.50% | 0.00% | 7.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.26 | -0.28 | -1.1 | -1.54 |
| 7 Days Ago | -0.28 | -0.29 | -1.12 | -1.52 |
| 30 Days Ago | -0.28 | -0.29 | -1.12 | -1.51 |
| 60 Days Ago | -0.28 | -0.29 | -1.13 | -1.48 |
| 90 Days Ago | -0.28 | -0.29 | -1.12 | -1.47 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | 4 | 4 | 4 |
| Up Last 30 Days | 3 | 4 | 4 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 4 | 5 | 6 |
Growth Estimates
| CURRENCY IN USD | VKTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -36.80% | -- | -- | 1.50% |
| Next Qtr. | -21.70% | -- | -- | 12.10% |
| Current Year | -20.90% | -- | -- | 4.40% |
| Next Year | -40.00% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 40.00% | -- | -- | 10.97% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/25/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/27/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 3/26/2024 |
| Maintains | BTIG: Buy to Buy | 3/26/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/26/2024 |
| Reiterates | Stifel: Buy to Buy | 3/15/2024 |
Related Tickers
MDGL Madrigal Pharmaceuticals, Inc.
194.38
-5.02%
NVO Novo Nordisk A/S
125.79
-0.29%
ALT Altimmune, Inc.
7.20
+1.69%
IOVA Iovance Biotherapeutics, Inc.
11.54
-1.45%
VRTX Vertex Pharmaceuticals Incorporated
397.70
-0.76%
RXRX Recursion Pharmaceuticals, Inc.
7.84
-1.26%
IBRX ImmunityBio, Inc.
5.11
+6.02%
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
CRSP CRISPR Therapeutics AG
53.73
-3.45%
JANX Janux Therapeutics, Inc.
47.10
-2.30%